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Background: This study aims to evaluate the relationship between serum thymus and activation-
regulated chemokine (TARC) levels with various clinicopathological conditions in patients with drug
eruptions. The value of TARC in diagnosing drug-induced hypersensitivity syndrome (DIHS) was also
examined.
Methods: Study participants included 84 patients who presented with generalized eruptions suspected
to be drug-related, including DIHS, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN),
maculopapular exanthema (MPE), erythema multiforme (EM), erythroderma, and toxicoderma. The
correlation coefﬁcients between serum TARC levels and clinical parameters in peripheral blood samples
were calculated.
Results: Serum TARC levels in patients with DIHS were higher than those found in patients with SJS/TEN,
MPE, EM, and toxicoderma. TARC levels had 100% sensitivity and 92.3% speciﬁcity in diagnosing DIHS,
with a threshold value of 13,900 pg/mL. Serum TARC levels positively correlated with age, white blood
cell (WBC) count, neutrophil count, eosinophil count, monocyte count, atypical lymphocyte (Aty-ly)
count, serum blood urea nitrogen (BUN) levels, and creatinine (Cr) levels. It negatively correlated with
serum total protein (TP), albumin (Alb), and estimated glomerular ﬁltration rate (eGFR). Among these
clinical parameters, blood eosinophil counts were most strongly correlated with serum TARC levels, with
a correlation coefﬁcient of 0.53.
Conclusions: Serum TARC levels are well correlated with blood eosinophil counts in patients with
generalized drug eruptions, indicating that Th2-type immune reactions underlie TARC production. Serum
TARC measurements also have potent diagnostic value for DIHS, with high sensitivity and speciﬁcity.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).y, Shimane University Faculty
1, Japan.
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Drug-induced hypersensitivity syndrome (DIHS) is a severe
adverse drug eruption, which has biphasic aspects of allergic re-
action to a drug and immune response to reactivation of a virus
such as the human herpes virus type-6 (HHV-6). The diagnostic
criteria for DIHS include seven clinical features: maculopapular
rash, prolonged clinical symptoms, high fever, leucocyte abnor-
malities, liver dysfunction, lymphadenopathy, and HHV-6 reac-
tivation.1 However, early diagnosis of DIHS may prove difﬁcult, not
only because diagnostic criteria include prolonged symptoms, but
also because its clinical features mimic maculopapular rash-type
drug reactions or eruptions due to viral infection.1
Recently, thymus and activation-regulated chemokine (TARC),
also known as CC chemokine ligand 17, has attracted attention as a
potential biomarker for DIHS diagnosis. TARC is one of the CC
chemokines that stimulates CC chemokine receptor 4 (CCR4),
which is expressed on type 2 helper T (Th2) lymphocytes.2 It re-
cruits CCR4þ Th2-polarized T lymphocytes into sites of local
inﬂammation, leading to a Th2-type immune response.3e5 Regu-
latory T cells (Tregs) are also reported to express CCR4.6 Since pa-
tients with atopic dermatitis (AD) show increased numbers of Th2
lymphocytes, serum TARC levels correlate with disease severity in
AD.7,8 In addition, stratum corneum TARC levels correlate with
severity of local skin inﬂammation in patients with AD.9
Recently, it has been reported that serum TARC levels are higher
in patients with DIHS than in patients with other severe drug
eruptions including Stevens-Johnson syndrome (SJS)/toxic
epidermal necrolysis (TEN) and maculopapular exanthema
(MPE).10,11 It has also been reported that serum TARC levels can be
used as a disease-speciﬁc diagnostic indicator of DIHS because
elevated levels are observed, especially at an early stage.12,13
However, studies to conﬁrm the diagnostic value of serum TARC
level for DIHS among patients with various types of drug eruptions,
including erythemamultiforme (EM) and erythroderma, are scarce.
The association of serum TARC levels with pathophysiological as-
pects of drug eruptions also remains unknown.
In the current study, serum TARC levels were examined in 67
patients who presented with generalized drug eruptions, including
DIHS, to conﬁrm the diagnostic value for DIHS and to investigate
the relationship of TARC to various clinical and laboratory param-
eters. Seventeen patients with toxicoderma, arising independently
from drug eruptions, were also included.Methods
Patients
Study participants included 84 patients (2e99 years; mean age
60.7 years) who presented with generalized eruptions suspected to
be drug-related at Shimane University Hospital from April 2014 to
September 2015. Of the 84 patients, 36 were male (3e89 years;
mean age 61.4 years), and 48 were female (2e99 years; mean ageTable 1
Background of the patients (n ¼ 84).
DIHS SJS/TEN
n 6 5
TARC (pg/mL) 31,713.8 ± 28,310.7 4702 ± 3582.1
Age (years) 76.0 ± 13.3 68.0 ± 24.0
Time lag of TARC measurement after onset (days) 11.6 ± 5.0 (n ¼ 5) 11.0 ± 12.0 (n
Data are presented as mean ± standard deviation (SD). DIHS, drug-induced hypersensitivi
maculopapular exanthema; EM, erythema multiforme. TARC, thymus and activation-reg60.1 years). The diagnoses of DIHS and SJS/TEN were performed
according to appropriate clinical criteria.1,14 The diagnosis of tox-
icoderma was assigned when no causal relationship to a drug was
detected, although initial clinical history and symptoms were
suggestive of a drug eruption. Final diagnoses were assigned as
follows: DIHS, 6 patients; SJS/TEN, 5 patients; MPE,14 patients; EM,
37 patients; erythroderma, 5 patients; and toxicoderma, 17 pa-
tients. The background proﬁles of these patients are presented in
Table 1 and Supplementary Table 1
The details of the study were fully explained to each patient or
his/her guardian and written informed consent was obtained. This
study was approved by the ethics committee of Shimane University
Faculty of Medicine (Approval No. 1746).
Measurement of serum TARC levels
In order to measure serum TARC levels, a chemiluminescent
enzyme immunoassay (CLEIA) was conducted, utilizing the HISCL®
system (Sysmex, Hyogo, Japan) with a TARC assay kit (Shionogi,
Osaka, Japan).13 Serum TARC levels were examined at ﬁrst visit to
our clinic and at several time points thereafter. Maximum serum
TARC levels represent the value reported for each patient.
Laboratory tests
Peripheral blood testing and biochemical examination were per-
formed during the study and results obtainedwithin the sameweek.
From these results, maximum TARC levels were evaluated for corre-
lation with serum TARC levels. The following biological parameters
were evaluated: white blood cell (WBC) count; neutrophil count;
eosinophil count; basophil count; monocyte count; lymphocyte
count; atypical lymphocyte (Aty-ly) count; redblood cell (RBC) count;
haemoglobin (Hb) level; platelet count; serum total bilirubin (T-bil)
level; total protein (TP) level; albumin (Alb) level; aspartate amino-
transferase (AST) level; alanine aminotransferase (ALT) level; lactate
dehydrogenase (LDH) level; alkaline phosphatase (Alp) level;
gamma-glutamyl transpeptidase (g-GTP) level; creatininekinase (CK)
level; bloodureanitrogen(BUN) level; creatinine (Cr) level;C-reactive
protein (CRP) level; total IgE level; andestimatedglomerularﬁltration
rate (eGFR). The eGFR was calculated according to the following
equations, which were proposed for estimating renal function of
Japanese patients: 194  Cr1.094  Age0.287 for male patients;
194 Cr1.094  Age0.287  0.739 for female patients.15
Data analysis
Unless otherwise indicated, data are presented as
mean ± standard deviation (SD). Statistical analysis was conducted
with SPSS software (version 22, Chicago, IL, USA). The Man-
neWhitney U-test was used for analysis between two groups. The
Spearman's rank correlation test was used for analysis of correla-
tion. Results were considered signiﬁcant when *P < 0.05, **P < 0.02
and ***P < 0.002.MPE EM Erythroderma Toxicoderma
14 37 5 17
5822.5 ± 9990.4 3748.6 ± 6561.9 11,605.5 ± 7341.9 1209.7 ± 1186.8
53.7 ± 20.8 62.8 ± 22.4 69.0 ± 11.9 52.3 ± 26.7
¼ 5) 5.5 ± 8.5 (n ¼ 13) 7.9 ± 9.5 (n ¼ 34) 8.0 ± 5.7 (n ¼ 2) 8.0 ± 11.3 (n ¼ 17)
ty syndrome; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; MPE,
ulated chemokine.
Fig. 1. (A) Serum TARC levels in the groups divided according to ﬁnal diagnosis (n ¼ 84). The results were considered to be statistically signiﬁcant when **P < 0.02, and ***P < 0.002
in ManneWhitney U-test. (B) Time-course of serum TARC levels of the patients with DIHS, MPE, EM, and erythroderma were presented. The day of consultation was set to be day
0 in the ﬁgure.
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Fig. 2. Receiver operating characteristic (ROC) curve in diagnosing DIHS (n ¼ 84).
Table 3
Correlation between serum TARC level and respective clinicopathological parame-
ters (n ¼ 84).
Variables Correlation coefﬁcients P
Age 0.38 <0.001***
WBCs 0.26 0.012**
Neutrophils 0.21 0.045*
Eosinophils 0.53 <0.001***
Basophils 0.15 0.153
Monocytes 0.26 0.015**
Lymphocytes 0.09 0.385
Atypical lymphocytes 0.25 0.019**
RBCs 0.14 0.183
Haemoglobin 0.12 0.282
Platelets 0.01 0.94
TP 0.30 0.004**
Alb 0.43 <0.001***
Total bilirubin 0.10 0.374
AST 0.06 0.601
ALT 0.02 0.887
LDH 0.16 0.126
Alp 0.00 0.984
g-GTP 0.06 0.643
CK 0.07 0.567
BUN 0.40 <0.001***
Cr 0.31 0.003**
CRP 0.08 0.484
IgE 0.24 0.098
eGFR 0.44 <0.001***
The results were considered to be statistically signiﬁcant when *P < 0.05, **P < 0.02,
and ***P < 0.002 in Spearman's rank correlation test. WBC, white blood cell; RBC, red
blood cell; TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; LDH, lactate dehydrogenase; Alp, alkaline phosphatase;
g-GTP, gamma-glutamyl transpeptidase; CK, creatinine kinase; BUN, blood urea
nitrogen; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; CRP, C-reactive
protein.
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Serum TARC levels in patient groups stratiﬁed by diagnosis
Mean serum TARC levels in patients grouped according to ﬁnal
diagnosis were as follows: patients with DIHS,
31,713.8 ± 28,310.7 pg/mL; SJS/TEN, 4702 ± 3582.1 pg/mL; MPE,
5822.5 ± 9990.4 pg/mL; EM, 3748.6 ± 6561.9 pg/mL; erythroderma
11,605.5 ± 7341.9 pg/mL; and toxicoderma, 1209.7 ± 1186.8 pg/mL
(Table 1). Serum TARC levels in patients with DIHS wereTable 2
Summary statistics of clinicopathological parameters according to ﬁnal diagnosis (n ¼ 8
DIHS (n ¼ 6) SJS/TEN (n ¼ 5) MPE (n
WBCs (/mL) 10,080.0 ± 3782.7 9476.0 ± 3320.8 7576.4
Neutrophils (/mL) 6642.0 ± 1985.8 7019.7 ± 3379.9 5064.0
Eosinophils (/mL) 1816.7 ± 1096.7 1153.6 ± 1723.5 470.5 ±
Basophils (/mL) 74.7 ± 24.2 94.5 ± 53.5 27.6 ±
Monocytes (/mL) 1023.4 ± 1344.3 626.2 ± 274.1 478.2 ±
Lymphocytes (/mL) 1442.5 ± 1044.1 1961.4 ± 525.6 1571.0
Atypical lymphocytes (/mL) 129.8 ± 192.8 23.6 ± 52.8 84.9 ±
RBCs (106/mL) 3.89 ± 0.41 4.21 ± 0.49 4.38 ±
Haemoglobin (g/dL) 11.78 ± 1.1 12.8 ± 1.6 13.1 ±
Platelets (103/mL) 334.0 ± 66.1 321.4 ± 31.1 268.8 ±
TP (g/dL) 5.90 ± 1.74 5.85 ± 1.14 5.99 ±
Alb (g/dL) 2.60 ± 1.09 2.85 ± 0.87 3.40 ±
Total bilirubin (mg/dL) 0.50 ± 0.23 0.55 ± 0.33 0.70 ±
AST (U/L) 89.5 ± 114.5 40.2 ± 22.7 37.1 ±
ALT (U/L) 110.8 ± 161.4 50.7 ± 39.0 45.6 ±
LDH (U/L) 323.6 ± 107.7 304.7 ± 85.1 257.0 ±
Alp (U/L) 307.2 ± 238.3 259.0 ± 249.6 205.1 ±
gGTP (U/L) 152.2 ± 263.4 88.7 ± 64.4 88.7 ±
CK (U/L) 36.2 ± 11.3 33.2 ± 29.6 52.5 ±
BUN (mg/dL) 23.5 ± 10.1 33.0 ± 36.3 21.3 ±
Cr (g/dL) 1.06 ± 0.38 2.15 ± 3.13 1.02 ±
CRP (g/dL) 4.01 ± 3.42 7.60 ± 4.67 4.45 ±
IgE (IU/mL) 164.6 ± 145.4 3128.5 ± 5927.1 178.7 ±
eGFR (mL/min/BSA) 54.6 ± 23.1 64.3 ± 41.9 69.36 ±
Data are presented as mean ± standard deviation (SD). DIHS, drug-induced hypersensitivi
maculopapular exanthema; EM, erythema multiforme. WBC, white blood cell; RBC, red
alanine aminotransferase; LDH, lactate dehydrogenase; Alp, alkaline phosphatase; g-GTP
Cr, creatinine; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate.signiﬁcantly higher than patients with SJS/TEN, MPE, EM and tox-
icoderma (Fig. 1A). The mean time-lag of TARC measurement after
onset was as follows: patients with DIHS, 11.6 ± 5.0 days; SJS/TEN,
11.0 ± 12.0 days; MPE, 5.5 ± 8.5 days; EM, 7.9 ± 9.5 days;4).
¼ 14) EM (n ¼ 37) Erythroderma (n ¼ 5) Toxicoderma
(n ¼ 17)
± 3619.5 7285.0 ± 3090.7 11,390.0 ± 2278.2 8385.0 ± 3884.8
± 3719.8 4937.9 ± 2968.4 9611.7 ± 3274.7 5957.4 ± 3128.6
660.6 629.8 ± 850.4 625.5 ± 518.1 379.4 ± 483.8
20.1 35.9 ± 30.5 44.9 ± 30.4 38.4 ± 21.6
214.7 469.4 ± 249.2 462.0 ± 179.0 540.3 ± 303.1
± 652.5 1533.2 ± 687.6 1507.4 ± 613.6 1808.6 ± 1734.1
235.6 37.1 ± 94.8 35.6 ± 61.7 16.1 ± 33.1
0.49 4.17 ± 0.63 4.14 ± 0.43 4.67 ± 2.33
1.1 12.6 ± 1.98 12.2 ± 1.86 13.8 ± 6.9
104.2 245.2 ± 85.2 329.2 ± 131.0 268.9 ± 85.4
0.88 6.73 ± 0.74 6.38 ± 1.25 6.23 ± 1.03
0.84 3.57 ± 0.64 3.03 ± 1.04 3.21 ± 0.61
0.36 1.42 ± 4.07 0.58 ± 0.13 1.42 ± 2.24
23.6 35.1 ± 41.7 37.6 ± 25.6 42.3 ± 36.0
50.3 37.9 ± 45.6 35.0 ± 14.2 36.6 ± 29.3
64.5 308.9 ± 211.1 356.0 ± 81.66 264.1 ± 98.3
59.6 295.8 ± 242.6 224.0 ± 2.83 300.6 ± 254.9
133.8 55.1 ± 76.0 34.4 ± 39.2 75.9 ± 106.3
31.3 68.5 ± 43.4 86.2 ± 45.6 136.3 ± 198.7
19.7 18.1 ± 10.5 26.7 ± 14.2 15.9 ± 7.6
1.13 0.81 ± 0.43 1.30 ± 0.69 0.72 ± 0.29
5.24 3.05 ± 3.41 2.14 ± 2.09 4.14 ± 4.29
283.8 771.0 ± 1338.8 2960.0 ± 4220.1 272.2 ± 332.1
24.7 76.4 ± 29.6 47.7 ± 16.4 79.7 ± 32.2
ty syndrome; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; MPE,
blood cell; TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT,
, gamma-glutamyl transpeptidase; CK, creatinine kinase; BUN, blood urea nitrogen;
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(Table 1). The time-course of serum TARC levels in patients with
DIHS, MPE, EM and erythroderma are shown in Figure 1B.
To assess the value of serum TARCmeasurements for diagnosing
DIHS, a receiver-operating characteristic (ROC) curve analysis was
conducted with a cut-off value of 13,900 pg/mL (n ¼ 84). Serum
TARC measurements were found to have a sensitivity of 100% (6/6
patients) and a speciﬁcity of 92.3% (72/78 patients) (Fig. 2).Fig. 3. (A) Clinicopathological parameters that are positively correlated with serum TARC le
respective scatter plots were all serum TARC level (log10). The results were considered to be
correlation test.Correlation of serum TARC levels with clinical parameters
Mean values of respective laboratory tests are presented in
Table 2. Serum TARC levels positively correlated with age, WBC
count, neutrophil count, eosinophil count, monocyte count, Aty-ly
count, serum BUN level and Cr level (Table 3). However, serum
TARC negatively correlated with serum TP level, Alb level and eGFR
(Table 3). Among these clinical parameters, blood eosinophil countsvel. (B) Negatively correlated with serum TARC level (n ¼ 84). Explanatory variables of
statistically signiﬁcant when *P < 0.05, **P < 0.02, and ***P < 0.002 in Spearman's rank
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highest correlation coefﬁcient of 0.53. However, no statistically
signiﬁcant correlation was observed between serum TARC levels
and blood basophil count, lymphocyte count, RBC count, haemo-
globin level, platelet count, serum T-bil level, AST level, ALT level,
LDH level, Alp level, g-GTP level, CK level, CRP level, or total IgE
level. Graphical representation of these correlations is shown in
scatter plots (Fig. 3A, B).Discussion
The present study demonstrates that serum TARC levels are
highly correlated with blood eosinophil count (correlation coefﬁ-
cient 0.53) in the patients studied. Our ﬁndings are consistent with
previous reports that indicate serum TARC levels in patients with
DIHS are signiﬁcantly higher than those in patients with SJS/TEN
and MPE.10,12 ROC curve analysis revealed the value of serum TARC
measurement in diagnosing DIHS with high sensitivity (100%) and
speciﬁcity (92.3%) at a cut-off value of 13,900 pg/mL. These results
support previous results that indicate serum TARC levels can be a
unique diagnostic marker of DIHS.12,13 In addition, 3/14 (21.4%)
patients with MPE, 2/37 (5.4%) patients with EM, and 1/5 (20%)
patients with erythroderma also had serum TARC levels over
13,900 pg/mL. These results indicate that these conditions share
some common pathophysiological aspects with DIHS.
Since DIHS is known to share similar characteristics with a
condition referred to as drug reaction with eosinophilia and sys-
temic symptoms (DRESS), which is characterized by blood eosin-
ophilia and organ damage,16 it is likely that our patients with MPE,
EM, and erythroderma fulﬁl the diagnostic criteria for DRESS. In
fact, four of these six (66.7%) patients showed scores higher than 4
when applying the scoring system for classifying DRESS,17 indi-
cating probable (deﬁnite) cases of DRESS.
Our results are partly consistent with a past report indicating a
Th-2 type immune reaction in patients with DIHS.18 We further
conclude that regardless of type of drug eruption, serumTARC levels
reﬂect an inﬂammatory condition of drug eruptionwhich results in
eosinophilia and is probably driven by Th-2 lymphocyte activation.
Another important ﬁnding of the present study is that serum
TARC levels positively correlate with BUN and Cr and negatively
correlate with eGFR. These data indicate that serum TARC is a good
indicator of renal failure in patients with drug eruptions. It is
intriguing that serum TARC correlates well with patient age, and
negatively with serum TP and Alb levels. This may reﬂect the fact
that aging or low ability for protein-synthesis tends to shift the
immune environment toward Th-2 lymphocyte-dominant activa-
tion. In addition, it is likely that patients in this group tended to
have a lower ability to metabolize drugs and were also taking
various drugs, resulting in relatively high blood concentrations of
drugs. A combination of these factors may lead to enhanced TARC
production in drug eruptions.19
We were unable to identify the TARC-producing cells. But it was
suggested that patients with MPE, SJS/TEN and EM have some
common clinical features with patients with DIHS. A previous pa-
per reported that TARCmay be expressed on CD11cþ dendritic cells
in the lesional dermis of patients with DIHS.12 It is therefore plau-
sible that dendritic cells in skin lesions of patients with MPE, SJS/
TEN and EM may also produce TARC, as is the case in patients with
DIHS.
This study had several limitations. Since only 84 patients were
enrolled, there is a possibility that statistical signiﬁcance was not
fully guaranteed. In addition, although some of the pathophysio-
logical aspects of drug eruptions were examined, it remains un-
known whether elevated serum TARC levels are associated withseverity of the drug eruption. In addition, the root cause of the drug
eruption remains unclear.
In conclusion, serum TARC levels are well correlated with blood
eosinophil counts in patients with generalized drug eruptions,
indicating that Th2-type immune reactions underlie TARC pro-
duction. Serum TARC level is also a good biomarker for diagnosing
DIHS/DRESS when drug reactions are suspected in patients pre-
senting with generalized rash.
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